Australia Medical Cannabis Market Size, Share & Trends Analysis Report By Application, By Sources (Hemp, Marijuana), By Derivatives (CBD, THC, Others), By Application (Cancer, Chronic Pain, Anxiety And Depression, Arthritis, Diabetes), And Segment Forecasts, 2026 - 2033
The Australia medical cannabis market size was estimated at USD 595.12 million in 2025 and is projected to reach USD 1,637.44 million by 2033, growing at a CAGR of 12.85% from 2026 to 2033. This growth is driven by a rising interest in alternative therapies for managing chronic pain, nausea, and various other health issues, the introduction of new products and formulations.
This growth in demand for non traditional therapeutic options reflects a shift in consumer preferences and a growing acknowledgment of the potential health benefits of these alternatives. The market is witnessing a significant increase in new and diverse product offerings, ranging from edibles and topicals.
In addition, number of people adopting cannabis for medical purposes has recently increased in Australia. According to findings from the 2022-23 National Drug Strategy Household Survey, conducted by the Australian Institute of Health and Welfare (AIHW), the use of cannabis for medical reasons has become increasingly common across Australia. The survey indicates that roughly three in every 100 Australians aged 14 years and older reported using cannabis for therapeutic purposes within the previous year, translating to an estimated population of about 700,000 individuals. This data reflects a trend in medical cannabis adoption, highlighting its growing role in symptom management and therapeutic care within the Australian healthcare landscape.
Moreover, the growth in patient numbers is matched by a rise in formal prescriptions, managed through access frameworks set by the Therapeutic Goods Administration (TGA). For instance, data from the TGA published in April 2024, show that since legal access pathways were established in 2016, approvals for medicinal cannabis products have grown substantially. In the end of 2023, there were over 963,000 approvals under the Authorized Prescriber (AP) pathway and around 458,000 approvals under the Special Access Scheme Category B (SAS-B) with chronic pain and anxiety among the top indications for use.
Australia Medical Cannabis Market Report Segmentation
This report forecasts revenue growth at country levels and provides an analysis on the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For the purpose of this study, Grand View Research has segmented the Australia medical cannabis market report on the basis of sources, derivatives, and application:
This report can be delivered to the clients within Immediate
This growth in demand for non traditional therapeutic options reflects a shift in consumer preferences and a growing acknowledgment of the potential health benefits of these alternatives. The market is witnessing a significant increase in new and diverse product offerings, ranging from edibles and topicals.
In addition, number of people adopting cannabis for medical purposes has recently increased in Australia. According to findings from the 2022-23 National Drug Strategy Household Survey, conducted by the Australian Institute of Health and Welfare (AIHW), the use of cannabis for medical reasons has become increasingly common across Australia. The survey indicates that roughly three in every 100 Australians aged 14 years and older reported using cannabis for therapeutic purposes within the previous year, translating to an estimated population of about 700,000 individuals. This data reflects a trend in medical cannabis adoption, highlighting its growing role in symptom management and therapeutic care within the Australian healthcare landscape.
Moreover, the growth in patient numbers is matched by a rise in formal prescriptions, managed through access frameworks set by the Therapeutic Goods Administration (TGA). For instance, data from the TGA published in April 2024, show that since legal access pathways were established in 2016, approvals for medicinal cannabis products have grown substantially. In the end of 2023, there were over 963,000 approvals under the Authorized Prescriber (AP) pathway and around 458,000 approvals under the Special Access Scheme Category B (SAS-B) with chronic pain and anxiety among the top indications for use.
Australia Medical Cannabis Market Report Segmentation
This report forecasts revenue growth at country levels and provides an analysis on the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For the purpose of this study, Grand View Research has segmented the Australia medical cannabis market report on the basis of sources, derivatives, and application:
- Sources Outlook (Revenue, USD Million, 2021 - 2033)
- Hemp
- Hemp CBD Oil
- Suppliments
- Industrial Hemp
- Marijuana
- Flower
- Oil and Tinctures
- Derivative Outlook (Revenue, USD Million, 2021 - 2033)
- CBD
- THC
- Others
- Application Outlook (Revenue, USD Million, 2021 - 2033)
- Cancer
- Chronic Pain
- Anxiety and Depression
- Arthritis
- Diabetes
- Glaucoma
- Migraines
- Epilepsy
- Multiple Sclerosis
- AIDS
- Amyotrophic Lateral Sclerosis
- Alzheimer’s Disease
- Post Traumatic Stress Disorder (PTSD)
- Parkinson's Disease
- Tourette’s Syndrome
- Others
This report can be delivered to the clients within Immediate
CHAPTER 1. METHODOLOGY AND SCOPE
1.1. Market Segmentation & Scope
1.1.1. Segment scope
1.1.2. Regional scope
1.1.3. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.6.1. Commodity flow analysis (Model 1)
1.6.1.1. Approach 1: Commodity flow approach
1.7. Research Assumptions
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Sources outlook
2.2.2. Derivatives outlook
2.2.3. End use outlook
2.3. Competitive Insights
CHAPTER 3. AUSTRALIA MEDICAL CANNABIS MARKET VARIABLES, TRENDS & SCOPE
3.1. Market Lineage Outlook
3.2. Parent Market Outlook
3.3. Ancillary Market Outlook
3.4. Market Dynamics
3.4.1. Market driver analysis
3.4.2. Market restraint analysis
3.5. Australia Medical Cannabis Market Analysis Tools
3.5.1. Industry Analysis - Porter’s Five Forces Analysis
3.5.2. PESTEL Analysis
3.6. Opportunity Analysis
3.7. Australia Medical Cannabis Potential Trade Opportunity, Australia
3.7.1. Medical Marijuana Trade Route
3.7.2. Hemp Trade Route
3.8. Value Chain Analysis
3.8.1. Raw Material Trends
3.8.2. Manufacturing Trends
3.9. Australia Medical Cannabis User Pool
3.9.1. Estimated Number Of Cannabis Users In Australia, 2021 - 2025 (In Thousands)
3.10. Market Trends in the Country
3.10.1. Introduction of New Cannabis Products
3.10.2. Celebrity Cannabis Engagement
3.10.3. Growing Popularity of Craft and Boutique Cannabis Brands
3.10.4. Improved Cannabis Cultivation and Distribution Technology
3.10.5. Federal and State Cannabis Policy Opportunities
3.11. Regulatory Scenario in Australia
3.11.1. Overview
3.11.2. Cannabis Cultivation Norms
3.11.3. Ease Of Cannabis Business
3.11.4. Competitive Landscape
3.11.5. Regulatory Bodies Involved
3.11.6. Licensing Scenario
3.11.7. Market Penetration
3.12. Jurisdiction Analysis in Australia
3.12.1. Legal Framework & Division Of Powers
3.12.2. Federal Regulation Of Medicinal Cannabis
3.12.3. Access Pathways
3.12.4. State & Territory Implementation
3.12.5. Clinical & Regulatory Oversight
3.13. Cannabis Consumption Pattern Analysis, Australia
3.14. Australia Medical Cannabis Potential Trade Opportunity, Australia
3.14.1. Global Medical Marijuana Trade Route
3.14.2. Global Hemp Trade Route
3.15. Australia Medical Cannabis Seed to Shelf Story
3.15.1. Section Description
3.15.2. Cultivators & Growers
3.15.3. Manufacturers & Producers
3.15.4. Testers
3.15.5. Wholesalers & Distributors
3.15.6. Retailers
3.16. Supply Chain Analysis
3.16.1. Supply Chain Network from Hemp Cultivators to CBD Consumer Products
3.16.2. Supply Chain Network of Hemp Biomass to Industrial Applications
3.16.3. Supply Chain Network from Marijuana Plants to Marijuana Oil
3.17. Profit Margin Analysis
3.18. Import & Domestic Production Analysis
3.18.1. Product Volume Analysis - Imports Vs Domestic Production (2024/2025)
3.18.2. Estimated Average Cost Per Gram - Domestic Vs Imports (2024 - 2025)
CHAPTER 4. AUSTRALIA MEDICAL CANNABIS MARKET: SOURCES ESTIMATES & TREND ANALYSIS
4.1. Definitions and Scope
4.2. Sources Segment Dashboard
4.3. Global Australia Medical Cannabis Market by Sources, 2021 to 2033
4.4. Marijuana
4.4.1. Marijuana market estimates and forecast 2021 to 2033 (USD Million)
4.4.2. Flower
4.4.2.1. Flower market estimates and forecast 2021 to 2033 (USD Million)
4.4.3. Oil and Tinctures
4.4.3.1. Oil and tinctures market estimates and forecast 2021 to 2033 (USD Million)
4.5. Hemp
4.5.1. Hemp market estimates and forecast 2021 to 2033 (USD Million)
4.5.2. Hemp CBD
4.5.2.1. Hemp CBD market estimates and forecast 2021 to 2033 (USD Million)
4.5.3. Supplements
4.5.3.1. Supplements market estimates and forecast 2021 to 2033 (USD Million)
4.5.4. Industrial Hemp
4.5.4.1. Industrial hemp market estimates and forecast 2021 to 2033 (USD Million)
CHAPTER 5. AUSTRALIA MEDICAL CANNABIS MARKET: DERIVATIVES ESTIMATES & TREND ANALYSIS
5.1. Definitions and Scope
5.2. Derivatives Segment Dashboard
5.3. Global Australia Medical Cannabis Market by Derivatives, 2021 to 2033
5.4. CBD
5.4.1. CBD market estimates and forecast 2021 to 2033 (USD Million)
5.5. THC
5.5.1. THC market estimates and forecast 2021 to 2033 (USD Million)
5.6. Others
5.6.1. Others market estimates and forecast 2021 to 2033 (USD Million)
CHAPTER 6. AUSTRALIA MEDICAL CANNABIS MARKET: APPLICATION ESTIMATES & TREND ANALYSIS
6.1. Definitions and Scope
6.2. Application Segment Dashboard
6.3. Australia Medical Cannabis Market: Application Movement Analysis
6.4. Australia Medical Cannabis Market by Application Outlook (USD Million)
6.5. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
6.6. Cancer
6.6.1. Cancer market estimates and forecast 2021 to 2033 (USD Million)
6.7. Chronic Pain
6.7.1. Chronic Pain market estimates and forecast 2021 to 2033 (USD Million)
6.8. Depression and Anxiety
6.8.1. Depression and anxiety market estimates and forecast 2021 to 2033 (USD Million)
6.9. Arthritis
6.9.1. Arthritis market estimates and forecast 2021 to 2033 (USD Million)
6.10. Diabetes
6.10.1. Diabetes market estimates and forecast 2021 to 2033 (USD Million)
6.11. Glaucoma
6.11.1. Glaucoma market estimates and forecast 2021 to 2033 (USD Million)
6.12. Migraines
6.12.1. Migraines market estimates and forecast 2021 to 2033 (USD Million)
6.13. Epilepsy
6.13.1. Epilepsy market estimates and forecast 2021 to 2033 (USD Million)
6.14. Multiple Sclerosis
6.14.1. Multiple sclerosis market estimates and forecast 2021 to 2033 (USD Million)
6.15. AIDS
6.15.1. AIDS market estimates and forecast 2021 to 2033 (USD Million)
6.16. Amyotrophic Lateral Sclerosis
6.16.1. Amyotrophic lateral sclerosis market estimates and forecast 2021 to 2033 (USD Million)
6.17. Alzheimer’s Disease
6.17.1. Alzheimer’s disease market estimates and forecast 2021 to 2033 (USD Million)
6.18. Post Traumatic Stress Disorder (PTSD)
6.18.1. Post Traumatic Stress Disorder (PTSD) market estimates and forecast 2021 to 2033 (USD Million)
6.19. Parkinson's Disease
6.19.1. Parkinson's disease market estimates and forecast 2021 to 2033 (USD Million)
6.20. Tourette’s Syndrome
6.20.1. Tourette’s syndrome market estimates and forecast 2021 to 2033 (USD Million)
6.21. Others
6.21.1. Others market estimates and forecast 2021 to 2033 (USD Million)
CHAPTER 7. COMPETITIVE LANDSCAPE
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Company/Competition Categorization
7.3. Company Market Position Analysis, 2025
7.4. Company Profiles
7.4.1. Cann Group
7.4.1.1. Company overview
7.4.1.2. Financial performance
7.4.1.3. Product benchmarking
7.4.1.4. Strategic initiatives
7.4.2. Zelira Therapeutics
7.4.2.1. Company overview
7.4.2.2. Financial performance
7.4.2.3. Product benchmarking
7.4.2.4. Strategic initiatives
7.4.3. AusCann Group Holdings Ltd
7.4.3.1. Company overview
7.4.3.2. Financial performance
7.4.3.3. Product benchmarking
7.4.3.4. Strategic initiatives
7.4.4. Bod Science
7.4.4.1. Company overview
7.4.4.2. Financial performance
7.4.4.3. Product benchmarking
7.4.4.4. Strategic initiatives
7.4.5. Althea Group
7.4.5.1. Company overview
7.4.5.2. Financial performance
7.4.5.3. Product benchmarking
7.4.5.4. Strategic initiatives
7.4.6. Ecofibre
7.4.6.1. Company overview
7.4.6.2. Financial performance
7.4.6.3. Product benchmarking
7.4.6.4. Strategic initiatives
7.4.7. Botanix SB Inc.
7.4.7.1. Company overview
7.4.7.2. Financial performance
7.4.7.3. Product benchmarking
7.4.7.4. Strategic initiatives
7.4.8. EPSILON
7.4.8.1. Company overview
7.4.8.2. Financial performance
7.4.8.3. Product benchmarking
7.4.8.4. Strategic initiatives
7.4.9. Little Green Pharma
7.4.9.1. Company overview
7.4.9.2. Financial performance
7.4.9.3. Product benchmarking
7.4.9.4. Strategic initiatives
7.4.10. Incannex Healthcare
7.4.10.1. Company overview
7.4.10.2. Financial performance
7.4.10.3. Product benchmarking
7.4.10.4. Strategic initiatives
7.4.11. Vitura Health Limited
7.4.11.1. Company overview
7.4.11.2. Financial performance
7.4.11.3. Product benchmarking
7.4.11.4. Strategic initiatives
7.4.12. Bioxyne
7.4.12.1. Company overview
7.4.12.2. Financial performance
7.4.12.3. Product benchmarking
7.4.12.4. Strategic initiatives
7.4.13. Green Farmers
7.4.13.1. Company overview
7.4.13.2. Financial performance
7.4.13.3. Product benchmarking
7.4.13.4. Strategic initiatives
7.4.14. ECS Botanics
7.4.14.1. Company overview
7.4.14.2. Financial performance
7.4.14.3. Product benchmarking
7.4.14.4. Strategic initiatives
7.4.15. Tasmanian Botanics
7.4.15.1. Company overview
7.4.15.2. Financial performance
7.4.15.3. Product benchmarking
7.4.15.4. Strategic initiatives
7.4.16. Cannatrek
7.4.16.1. Company overview
7.4.16.2. Financial performance
7.4.16.3. Product benchmarking
7.4.16.4. Strategic initiatives
7.4.17. Hale farms
7.4.17.1. Company overview
7.4.17.2. Financial performance
7.4.17.3. Product benchmarking
7.4.17.4. Strategic initiatives
7.4.18. Australian Natural Therapeutics Group
7.4.18.1. Company overview
7.4.18.2. Financial performance
7.4.18.3. Product benchmarking
7.4.18.4. Strategic initiatives
7.4.19. MedTEC Pharma
7.4.19.1. Company overview
7.4.19.2. Financial performance
7.4.19.3. Product benchmarking
7.4.19.4. Strategic initiatives
7.4.20. Aruma Labs
7.4.20.1. Company overview
7.4.20.2. Financial performance
7.4.20.3. Product benchmarking
7.4.20.4. Strategic initiatives
7.4.21. Montu Group
7.4.21.1. Company overview
7.4.21.2. Financial performance
7.4.21.3. Product benchmarking
7.4.21.4. Strategic initiatives
1.1. Market Segmentation & Scope
1.1.1. Segment scope
1.1.2. Regional scope
1.1.3. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.6.1. Commodity flow analysis (Model 1)
1.6.1.1. Approach 1: Commodity flow approach
1.7. Research Assumptions
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Sources outlook
2.2.2. Derivatives outlook
2.2.3. End use outlook
2.3. Competitive Insights
CHAPTER 3. AUSTRALIA MEDICAL CANNABIS MARKET VARIABLES, TRENDS & SCOPE
3.1. Market Lineage Outlook
3.2. Parent Market Outlook
3.3. Ancillary Market Outlook
3.4. Market Dynamics
3.4.1. Market driver analysis
3.4.2. Market restraint analysis
3.5. Australia Medical Cannabis Market Analysis Tools
3.5.1. Industry Analysis - Porter’s Five Forces Analysis
3.5.2. PESTEL Analysis
3.6. Opportunity Analysis
3.7. Australia Medical Cannabis Potential Trade Opportunity, Australia
3.7.1. Medical Marijuana Trade Route
3.7.2. Hemp Trade Route
3.8. Value Chain Analysis
3.8.1. Raw Material Trends
3.8.2. Manufacturing Trends
3.9. Australia Medical Cannabis User Pool
3.9.1. Estimated Number Of Cannabis Users In Australia, 2021 - 2025 (In Thousands)
3.10. Market Trends in the Country
3.10.1. Introduction of New Cannabis Products
3.10.2. Celebrity Cannabis Engagement
3.10.3. Growing Popularity of Craft and Boutique Cannabis Brands
3.10.4. Improved Cannabis Cultivation and Distribution Technology
3.10.5. Federal and State Cannabis Policy Opportunities
3.11. Regulatory Scenario in Australia
3.11.1. Overview
3.11.2. Cannabis Cultivation Norms
3.11.3. Ease Of Cannabis Business
3.11.4. Competitive Landscape
3.11.5. Regulatory Bodies Involved
3.11.6. Licensing Scenario
3.11.7. Market Penetration
3.12. Jurisdiction Analysis in Australia
3.12.1. Legal Framework & Division Of Powers
3.12.2. Federal Regulation Of Medicinal Cannabis
3.12.3. Access Pathways
3.12.4. State & Territory Implementation
3.12.5. Clinical & Regulatory Oversight
3.13. Cannabis Consumption Pattern Analysis, Australia
3.14. Australia Medical Cannabis Potential Trade Opportunity, Australia
3.14.1. Global Medical Marijuana Trade Route
3.14.2. Global Hemp Trade Route
3.15. Australia Medical Cannabis Seed to Shelf Story
3.15.1. Section Description
3.15.2. Cultivators & Growers
3.15.3. Manufacturers & Producers
3.15.4. Testers
3.15.5. Wholesalers & Distributors
3.15.6. Retailers
3.16. Supply Chain Analysis
3.16.1. Supply Chain Network from Hemp Cultivators to CBD Consumer Products
3.16.2. Supply Chain Network of Hemp Biomass to Industrial Applications
3.16.3. Supply Chain Network from Marijuana Plants to Marijuana Oil
3.17. Profit Margin Analysis
3.18. Import & Domestic Production Analysis
3.18.1. Product Volume Analysis - Imports Vs Domestic Production (2024/2025)
3.18.2. Estimated Average Cost Per Gram - Domestic Vs Imports (2024 - 2025)
CHAPTER 4. AUSTRALIA MEDICAL CANNABIS MARKET: SOURCES ESTIMATES & TREND ANALYSIS
4.1. Definitions and Scope
4.2. Sources Segment Dashboard
4.3. Global Australia Medical Cannabis Market by Sources, 2021 to 2033
4.4. Marijuana
4.4.1. Marijuana market estimates and forecast 2021 to 2033 (USD Million)
4.4.2. Flower
4.4.2.1. Flower market estimates and forecast 2021 to 2033 (USD Million)
4.4.3. Oil and Tinctures
4.4.3.1. Oil and tinctures market estimates and forecast 2021 to 2033 (USD Million)
4.5. Hemp
4.5.1. Hemp market estimates and forecast 2021 to 2033 (USD Million)
4.5.2. Hemp CBD
4.5.2.1. Hemp CBD market estimates and forecast 2021 to 2033 (USD Million)
4.5.3. Supplements
4.5.3.1. Supplements market estimates and forecast 2021 to 2033 (USD Million)
4.5.4. Industrial Hemp
4.5.4.1. Industrial hemp market estimates and forecast 2021 to 2033 (USD Million)
CHAPTER 5. AUSTRALIA MEDICAL CANNABIS MARKET: DERIVATIVES ESTIMATES & TREND ANALYSIS
5.1. Definitions and Scope
5.2. Derivatives Segment Dashboard
5.3. Global Australia Medical Cannabis Market by Derivatives, 2021 to 2033
5.4. CBD
5.4.1. CBD market estimates and forecast 2021 to 2033 (USD Million)
5.5. THC
5.5.1. THC market estimates and forecast 2021 to 2033 (USD Million)
5.6. Others
5.6.1. Others market estimates and forecast 2021 to 2033 (USD Million)
CHAPTER 6. AUSTRALIA MEDICAL CANNABIS MARKET: APPLICATION ESTIMATES & TREND ANALYSIS
6.1. Definitions and Scope
6.2. Application Segment Dashboard
6.3. Australia Medical Cannabis Market: Application Movement Analysis
6.4. Australia Medical Cannabis Market by Application Outlook (USD Million)
6.5. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
6.6. Cancer
6.6.1. Cancer market estimates and forecast 2021 to 2033 (USD Million)
6.7. Chronic Pain
6.7.1. Chronic Pain market estimates and forecast 2021 to 2033 (USD Million)
6.8. Depression and Anxiety
6.8.1. Depression and anxiety market estimates and forecast 2021 to 2033 (USD Million)
6.9. Arthritis
6.9.1. Arthritis market estimates and forecast 2021 to 2033 (USD Million)
6.10. Diabetes
6.10.1. Diabetes market estimates and forecast 2021 to 2033 (USD Million)
6.11. Glaucoma
6.11.1. Glaucoma market estimates and forecast 2021 to 2033 (USD Million)
6.12. Migraines
6.12.1. Migraines market estimates and forecast 2021 to 2033 (USD Million)
6.13. Epilepsy
6.13.1. Epilepsy market estimates and forecast 2021 to 2033 (USD Million)
6.14. Multiple Sclerosis
6.14.1. Multiple sclerosis market estimates and forecast 2021 to 2033 (USD Million)
6.15. AIDS
6.15.1. AIDS market estimates and forecast 2021 to 2033 (USD Million)
6.16. Amyotrophic Lateral Sclerosis
6.16.1. Amyotrophic lateral sclerosis market estimates and forecast 2021 to 2033 (USD Million)
6.17. Alzheimer’s Disease
6.17.1. Alzheimer’s disease market estimates and forecast 2021 to 2033 (USD Million)
6.18. Post Traumatic Stress Disorder (PTSD)
6.18.1. Post Traumatic Stress Disorder (PTSD) market estimates and forecast 2021 to 2033 (USD Million)
6.19. Parkinson's Disease
6.19.1. Parkinson's disease market estimates and forecast 2021 to 2033 (USD Million)
6.20. Tourette’s Syndrome
6.20.1. Tourette’s syndrome market estimates and forecast 2021 to 2033 (USD Million)
6.21. Others
6.21.1. Others market estimates and forecast 2021 to 2033 (USD Million)
CHAPTER 7. COMPETITIVE LANDSCAPE
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Company/Competition Categorization
7.3. Company Market Position Analysis, 2025
7.4. Company Profiles
7.4.1. Cann Group
7.4.1.1. Company overview
7.4.1.2. Financial performance
7.4.1.3. Product benchmarking
7.4.1.4. Strategic initiatives
7.4.2. Zelira Therapeutics
7.4.2.1. Company overview
7.4.2.2. Financial performance
7.4.2.3. Product benchmarking
7.4.2.4. Strategic initiatives
7.4.3. AusCann Group Holdings Ltd
7.4.3.1. Company overview
7.4.3.2. Financial performance
7.4.3.3. Product benchmarking
7.4.3.4. Strategic initiatives
7.4.4. Bod Science
7.4.4.1. Company overview
7.4.4.2. Financial performance
7.4.4.3. Product benchmarking
7.4.4.4. Strategic initiatives
7.4.5. Althea Group
7.4.5.1. Company overview
7.4.5.2. Financial performance
7.4.5.3. Product benchmarking
7.4.5.4. Strategic initiatives
7.4.6. Ecofibre
7.4.6.1. Company overview
7.4.6.2. Financial performance
7.4.6.3. Product benchmarking
7.4.6.4. Strategic initiatives
7.4.7. Botanix SB Inc.
7.4.7.1. Company overview
7.4.7.2. Financial performance
7.4.7.3. Product benchmarking
7.4.7.4. Strategic initiatives
7.4.8. EPSILON
7.4.8.1. Company overview
7.4.8.2. Financial performance
7.4.8.3. Product benchmarking
7.4.8.4. Strategic initiatives
7.4.9. Little Green Pharma
7.4.9.1. Company overview
7.4.9.2. Financial performance
7.4.9.3. Product benchmarking
7.4.9.4. Strategic initiatives
7.4.10. Incannex Healthcare
7.4.10.1. Company overview
7.4.10.2. Financial performance
7.4.10.3. Product benchmarking
7.4.10.4. Strategic initiatives
7.4.11. Vitura Health Limited
7.4.11.1. Company overview
7.4.11.2. Financial performance
7.4.11.3. Product benchmarking
7.4.11.4. Strategic initiatives
7.4.12. Bioxyne
7.4.12.1. Company overview
7.4.12.2. Financial performance
7.4.12.3. Product benchmarking
7.4.12.4. Strategic initiatives
7.4.13. Green Farmers
7.4.13.1. Company overview
7.4.13.2. Financial performance
7.4.13.3. Product benchmarking
7.4.13.4. Strategic initiatives
7.4.14. ECS Botanics
7.4.14.1. Company overview
7.4.14.2. Financial performance
7.4.14.3. Product benchmarking
7.4.14.4. Strategic initiatives
7.4.15. Tasmanian Botanics
7.4.15.1. Company overview
7.4.15.2. Financial performance
7.4.15.3. Product benchmarking
7.4.15.4. Strategic initiatives
7.4.16. Cannatrek
7.4.16.1. Company overview
7.4.16.2. Financial performance
7.4.16.3. Product benchmarking
7.4.16.4. Strategic initiatives
7.4.17. Hale farms
7.4.17.1. Company overview
7.4.17.2. Financial performance
7.4.17.3. Product benchmarking
7.4.17.4. Strategic initiatives
7.4.18. Australian Natural Therapeutics Group
7.4.18.1. Company overview
7.4.18.2. Financial performance
7.4.18.3. Product benchmarking
7.4.18.4. Strategic initiatives
7.4.19. MedTEC Pharma
7.4.19.1. Company overview
7.4.19.2. Financial performance
7.4.19.3. Product benchmarking
7.4.19.4. Strategic initiatives
7.4.20. Aruma Labs
7.4.20.1. Company overview
7.4.20.2. Financial performance
7.4.20.3. Product benchmarking
7.4.20.4. Strategic initiatives
7.4.21. Montu Group
7.4.21.1. Company overview
7.4.21.2. Financial performance
7.4.21.3. Product benchmarking
7.4.21.4. Strategic initiatives
LIST OF TABLES
Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 Australia medical cannabis market, by source, 2021 - 2033 (USD Million)
Table 4 Australia medical cannabis market, by derivatives, 2021 - 2033 (USD Million)
Table 5 Australia medical cannabis market, by end use, 2021 - 2033 (USD Million)
Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 Australia medical cannabis market, by source, 2021 - 2033 (USD Million)
Table 4 Australia medical cannabis market, by derivatives, 2021 - 2033 (USD Million)
Table 5 Australia medical cannabis market, by end use, 2021 - 2033 (USD Million)
LIST OF FIGURES
Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value chain-based sizing & forecasting
Fig. 6 Market formulation & validation
Fig. 7 Australia medical cannabis market: market outlook
Fig. 8 Australia medical cannabis competitive insights
Fig. 9 Parent market outlook
Fig. 10 Related/ancillary market outlook
Fig. 11 Penetration and growth prospect mapping
Fig. 12 Industry value chain analysis
Fig. 13 Australia medical cannabis market driver impact
Fig. 14 Australia medical cannabis market restraint impact
Fig. 15 Porter’s Analysis
Fig. 16 PESTLE Analysis
Fig. 17 Australia medical cannabis market: Sources movement analysis
Fig. 18 Australia medical cannabis market: Sources outlook and key takeaways
Fig. 19 Marijuana market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 20 Flower market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 21 Oil & tinctures market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 22 Hemp market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 23 Hemp CBD market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 24 Supplements market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 25 Industrial hemp market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 26 Australia medical cannabis market: Derivatives movement analysis
Fig. 27 Australia medical cannabis market: Derivatives outlook and key takeaways
Fig. 28 CBD market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 29 THC market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 30 Others market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 31 Australia medical cannabis market: Application movement analysis
Fig. 32 Australia medical cannabis market: Application outlook and key takeaways
Fig. 33 Cancer market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 34 Chronic Pain market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 35 Depression and anxiety market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 36 Arthritis market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 37 Diabetes market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 38 Glaucoma market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 39 Migraines market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 40 Epilepsy market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 41 Multiple Sclerosis market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 42 AIDS market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 43 Amyotrophic Lateral Sclerosis market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 44 Alzheimer market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 45 Post Traumatic Stress Disorder (PTSD) market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 46 Parkinson's disease market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 47 Tourette market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 48 Industrial market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 49 Key company categorization
Fig. 50 Heat map analysis, 2025
Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value chain-based sizing & forecasting
Fig. 6 Market formulation & validation
Fig. 7 Australia medical cannabis market: market outlook
Fig. 8 Australia medical cannabis competitive insights
Fig. 9 Parent market outlook
Fig. 10 Related/ancillary market outlook
Fig. 11 Penetration and growth prospect mapping
Fig. 12 Industry value chain analysis
Fig. 13 Australia medical cannabis market driver impact
Fig. 14 Australia medical cannabis market restraint impact
Fig. 15 Porter’s Analysis
Fig. 16 PESTLE Analysis
Fig. 17 Australia medical cannabis market: Sources movement analysis
Fig. 18 Australia medical cannabis market: Sources outlook and key takeaways
Fig. 19 Marijuana market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 20 Flower market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 21 Oil & tinctures market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 22 Hemp market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 23 Hemp CBD market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 24 Supplements market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 25 Industrial hemp market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 26 Australia medical cannabis market: Derivatives movement analysis
Fig. 27 Australia medical cannabis market: Derivatives outlook and key takeaways
Fig. 28 CBD market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 29 THC market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 30 Others market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 31 Australia medical cannabis market: Application movement analysis
Fig. 32 Australia medical cannabis market: Application outlook and key takeaways
Fig. 33 Cancer market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 34 Chronic Pain market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 35 Depression and anxiety market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 36 Arthritis market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 37 Diabetes market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 38 Glaucoma market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 39 Migraines market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 40 Epilepsy market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 41 Multiple Sclerosis market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 42 AIDS market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 43 Amyotrophic Lateral Sclerosis market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 44 Alzheimer market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 45 Post Traumatic Stress Disorder (PTSD) market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 46 Parkinson's disease market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 47 Tourette market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 48 Industrial market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 49 Key company categorization
Fig. 50 Heat map analysis, 2025
